127 related articles for article (PubMed ID: 19860684)
1. Simultaneous optimization of potency, selectivity and physicochemical properties for cannabinoid CB(2) ligands.
Worm K; Dolle RE
Curr Pharm Des; 2009; 15(29):3345-66. PubMed ID: 19860684
[TBL] [Abstract][Full Text] [Related]
2. Updating the chemistry and biology of cannabinoid CB2 receptor-specific inverse agonists.
Lunn CA
Curr Top Med Chem; 2010; 10(8):768-78. PubMed ID: 20370714
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor.
Marriott KS; Huffman JW
Curr Top Med Chem; 2008; 8(3):187-204. PubMed ID: 18289088
[TBL] [Abstract][Full Text] [Related]
4. Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands.
Atwood BK; Wager-Miller J; Haskins C; Straiker A; Mackie K
Mol Pharmacol; 2012 Feb; 81(2):250-63. PubMed ID: 22064678
[TBL] [Abstract][Full Text] [Related]
5. Targeting cannabinoid agonists for inflammatory and neuropathic pain.
Cheng Y; Hitchcock SA
Expert Opin Investig Drugs; 2007 Jul; 16(7):951-65. PubMed ID: 17594182
[TBL] [Abstract][Full Text] [Related]
6. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands.
Poso A; Huffman JW
Br J Pharmacol; 2008 Jan; 153(2):335-46. PubMed ID: 17982473
[TBL] [Abstract][Full Text] [Related]
7. CB2 receptor ligands.
Huffman JW
Mini Rev Med Chem; 2005 Jul; 5(7):641-9. PubMed ID: 16026310
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches.
Reggio PH
Handb Exp Pharmacol; 2005; (168):247-81. PubMed ID: 16596777
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes.
Huffman JW; Padgett LW
Curr Med Chem; 2005; 12(12):1395-411. PubMed ID: 15974991
[TBL] [Abstract][Full Text] [Related]
10. Strategies to develop selective CB
Moir M; Lane S; Lai F; Connor M; Hibbs DE; Kassiou M
Eur J Med Chem; 2019 Oct; 180():291-309. PubMed ID: 31319265
[TBL] [Abstract][Full Text] [Related]
11. Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis.
Floresta G; Apirakkan O; Rescifina A; Abbate V
Molecules; 2018 Aug; 23(9):. PubMed ID: 30200181
[TBL] [Abstract][Full Text] [Related]
12. Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.
Foloppe N; Benwell K; Brooks TD; Kennett G; Knight AR; Misra A; Monck NJ
Bioorg Med Chem Lett; 2009 Aug; 19(15):4183-90. PubMed ID: 19520572
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel class of selective human CB1 inverse agonists.
Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
[TBL] [Abstract][Full Text] [Related]
14. Recent development of CB2 selective and peripheral CB1/CB2 cannabinoid receptor ligands.
Nevalainen T
Curr Med Chem; 2014; 21(2):187-203. PubMed ID: 24164198
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.
Reggio PH
Curr Pharm Des; 2003; 9(20):1607-33. PubMed ID: 12871061
[TBL] [Abstract][Full Text] [Related]
16. N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
Ohta H; Ishizaka T; Tatsuzuki M; Yoshinaga M; Iida I; Tomishima Y; Toda Y; Saito S
Bioorg Med Chem Lett; 2007 Nov; 17(22):6299-304. PubMed ID: 17884496
[TBL] [Abstract][Full Text] [Related]
17. Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
Blaazer AR; Lange JH; van der Neut MA; Mulder A; den Boon FS; Werkman TR; Kruse CG; Wadman WJ
Eur J Med Chem; 2011 Oct; 46(10):5086-98. PubMed ID: 21885167
[TBL] [Abstract][Full Text] [Related]
18. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
19. Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future.
Whiting ZM; Yin J; de la Harpe SM; Vernall AJ; Grimsey NL
Trends Pharmacol Sci; 2022 Sep; 43(9):754-771. PubMed ID: 35906103
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Han S; Thatte J; Buzard DJ; Jones RM
J Med Chem; 2013 Nov; 56(21):8224-56. PubMed ID: 23865723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
